$ICCC
IMMUCELL CORP /DE/ Stock $iccc

$iccc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022046861 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$4.796M	$3.861M	$6.000M
YoY Change	-6.88%	-14.98%	45.98%
Cost Of Revenue	$2.950M	$2.154M	$2.896M
YoY Change	8.0%	-12.7%	15.86%
Gross Profit	$1.846M	$1.707M	$3.103M
YoY Change	-23.68%	-17.69%	93.95%
Gross Profit Margin	38.49%	44.22%	51.72%
Selling, General & Admin	$1.193M	$1.188M	$1.274M
YoY Change	8.45%	38.3%	34.14%
% of Gross Profit	64.63%	69.56%	41.06%
Research & Development	$1.270M	$1.139M	$1.036M
YoY Change	21.22%	13.86%	0.58%
% of Gross Profit	68.78%	66.7%	33.38%
Depreciation & Amortization	$627.5K	$624.6K	$621.6K
YoY Change	1.52%	1.15%	1.91%
% of Gross Profit	33.99%	36.58%	20.03%
Operating Expenses	$2.463M	$2.326M	$2.310M
YoY Change	14.68%	25.15%	16.68%
Operating Profit	-$616.8K	-$619.0K	$793.0K
YoY Change	-327.52%	-387.23%	-308.68%
Interest Expense	$89.43K	$90.24K	-$68.02K
YoY Change	-222.49%	13.63%	-14.98%
% of Operating Profit			-8.58%
Other Income/Expense, Net	-$34.42K	-$63.99K	$850.00
YoY Change	-70.14%	-13.98%
Pretax Income	-$651.2K	-$683.0K	$736.8K
YoY Change	-517.95%	-584.01%	-267.46%
Income Tax	$3.867K	$1.148K	$1.150K
% Of Pretax Income			0.16%
Net Earnings	-$655.1K	-$684.1K	$735.7K
YoY Change	-543.34%	-584.82%	-267.2%
Net Earnings / Revenue	-13.66%	-17.72%	12.26%
Basic Earnings Per Share	-$0.08	-$0.09	$0.07
Diluted Earnings Per Share	-$0.08	-$0.09	$94.44K
COMMON SHARES
Basic Shares Outstanding	7.747M shares	7.745M shares	7.742M shares
Diluted Shares Outstanding	7.747M shares	7.745M shares	7.789M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.828M	$11.04M	$11.82M
YoY Change	-15.89%	3.2%	73.53%
Cash & Equivalents	$8.828M	$11.04M	$11.82M
Short-Term Investments			$0.00
Other Short-Term Assets	$552.4K	$244.3K	$387.4K
YoY Change	16.3%	-29.84%	-3.15%
Inventory	$5.318M	$4.603M	$3.436M
Prepaid Expenses
Receivables	$1.702M	$1.414M	$2.653M
Other Receivables	$33.29K	$24.09K	$6.150K
Total Short-Term Assets	$16.43M	$17.33M	$18.30M
YoY Change	2.22%	11.56%	54.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.57M	$27.42M	$28.21M
YoY Change	-1.37%	-2.05%	2.21%
Goodwill	$95.56K	$95.56K
YoY Change
Intangibles	$62.09K	$66.86K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$24.57K	$23.78K	$23.00K
YoY Change	-7.64%	-6.33%	15.0%
Total Long-Term Assets	$29.97M	$28.66M	$28.40M
YoY Change	6.44%	1.62%	2.12%
TOTAL ASSETS
Total Short-Term Assets	$16.43M	$17.33M	$18.30M
Total Long-Term Assets	$29.97M	$28.66M	$28.40M
Total Assets	$46.40M	$45.98M	$46.70M
YoY Change	4.91%	5.15%	17.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$759.3K	$643.9K	$662.1K
YoY Change	7.96%	19.95%	-10.53%
Accrued Expenses	$691.6K	$632.3K	$491.4K
YoY Change	43.59%	19.8%	9.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$998.2K	$967.0K	$947.3K
YoY Change	27.56%	24.78%	23.02%
Total Short-Term Liabilities	$2.715M	$2.509M	$2.351M
YoY Change	25.36%	23.46%	11.96%
LONG-TERM LIABILITIES
Long-Term Debt	$9.479M	$9.731M	$9.978M
YoY Change	10.86%	16.57%	16.84%
Other Long-Term Liabilities	$2.225M	$969.1K	$998.1K
YoY Change	111.1%	-10.37%	-10.08%
Total Long-Term Liabilities	$11.70M	$10.70M	$10.98M
YoY Change	21.87%	13.48%	13.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.715M	$2.509M	$2.351M
Total Long-Term Liabilities	$11.70M	$10.70M	$10.98M
Total Liabilities	$14.42M	$13.21M	$13.33M
YoY Change	22.51%	15.25%	13.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.565M	-$3.687M
YoY Change
Common Stock	$781.4K	$781.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$147.2K	$147.2K
YoY Change
Treasury Stock Shares	67.30K shares	67.30K shares
Shareholders Equity	$31.98M	$32.77M	$33.37M
YoY Change
Total Liabilities & Shareholders Equity	$46.40M	$45.98M	$46.70M
YoY Change	4.91%	5.15%	17.87%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$655.1K	-$684.1K	$735.7K
YoY Change	-543.34%	-584.82%	-267.2%
Depreciation, Depletion And Amortization	$627.5K	$624.6K	$621.6K
YoY Change	1.52%	1.15%	1.91%
Cash From Operating Activities	-$1.258M	$373.4K	$638.5K
YoY Change	-585.75%	-48.65%	-202.99%
INVESTING ACTIVITIES
Capital Expenditures	-$734.3K	-$943.3K	-$807.5K
YoY Change	8.72%	7.36%	130.71%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$11.00K
YoY Change	-100.0%	-100.0%	-98.91%
Cash From Investing Activities	-$734.3K	-$943.3K	-$796.5K
YoY Change	9.37%	6.87%	-220.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-223.1K	-204.1K	1.790M
YoY Change	-207.44%	-105.04%	-1094.24%
NET CHANGE
Cash From Operating Activities	-1.258M	373.4K	638.5K
Cash From Investing Activities	-734.3K	-943.3K	-796.5K
Cash From Financing Activities	-223.1K	-204.1K	1.790M
Net Change In Cash	-2.215M	-773.9K	1.632M
YoY Change	981.87%	-119.89%	-1265.48%
FREE CASH FLOW
Cash From Operating Activities	-$1.258M	$373.4K	$638.5K
Capital Expenditures	-$734.3K	-$943.3K	-$807.5K
Free Cash Flow	-$523.7K	$1.317M	$1.446M
YoY Change	-156.05%	-18.01%	-635.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Security12b Title Security12bTitle	Common Stock, $0.10 par value per share
	dei	Trading Symbol TradingSymbol	ICCC
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity File Number EntityFileNumber	001-12934
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7440237	shares
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7746864	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11043225	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10185468	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1413704	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2694229	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4603109	usd
	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P7Y7M6D
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P10Y
CY2021Q4	us-gaap	Inventory Net InventoryNet	3089974	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	268350	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295197	usd
	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P8Y7M6D
CY2022Q2	us-gaap	Assets Current AssetsCurrent	17328388	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	16264868	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27418130	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26893599	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051127	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1109133	usd
CY2022Q2	us-gaap	Goodwill Goodwill	95557	usd
CY2021Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	66864	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76416	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.25
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7746864	shares
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	01-0382980
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7741864	shares
	dei	Entity Address Address Line1 EntityAddressAddressLine1	56 Evergreen Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Portland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	ME
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	04103
CY2021Q4	us-gaap	Liabilities Liabilities	11888748	usd
	dei	City Area Code CityAreaCode	(207)
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
	dei	Local Phone Number LocalPhoneNumber	878-2770
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23783	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26115	usd
CY2022Q2	us-gaap	Assets Assets	45983849	usd
CY2021Q4	us-gaap	Assets Assets	44465688	usd
CY2022Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	966996	usd
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	812207	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	112092	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108012	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1429797	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1614250	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2508885	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2534469	usd
CY2022Q2	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	9731030	usd
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	8327122	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	969077	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1027157	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10700107	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9354279	usd
CY2022Q2	us-gaap	Liabilities Liabilities	13208992	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35827848	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35692388	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3687176	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3738694	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	67301	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	72301	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	147232	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	158171	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	32774857	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32576940	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45983849	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44465688	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3861372	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4541810	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9861056	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8648956	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2154044	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2467489	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5050505	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4972446	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1707328	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	2074321	usd
	us-gaap	Gross Profit GrossProfit	4810551	usd
	us-gaap	Gross Profit GrossProfit	3676510	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1138767	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000107	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2174702	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2031171	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	659239	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	436982	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1470740	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	957580	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	528329	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	421724	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	991129	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	846876	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2326335	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1858813	usd
	us-gaap	Operating Expenses OperatingExpenses	4636571	usd
	us-gaap	Operating Expenses OperatingExpenses	3835627	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-619007	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	215508	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	173980	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-159117	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63993	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74395	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-120167	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-141073	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-683000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	141113	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	53813	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-300190	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1148	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2295	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-684148	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	141113	usd
	us-gaap	Net Income Loss NetIncomeLoss	51518	usd
	us-gaap	Net Income Loss NetIncomeLoss	-300190	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7744567	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7658612	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7743350	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7744567	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7761056	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7781403	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7440237	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	33372539	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-684148	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24831	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	61635	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	32774857	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	27871206	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	141113	usd
CY2021Q2	iccc	Public Offering Of Common Stock PublicOfferingOfCommonStock	17011	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4233026	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	23265	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	32268623	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32576940	usd
	us-gaap	Net Income Loss NetIncomeLoss	51518	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30672	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	115727	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	32774857	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28266200	usd
	us-gaap	Net Income Loss NetIncomeLoss	-300190	usd
	iccc	Public Offering Of Common Stock PublicOfferingOfCommonStock	17011	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4233026	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11693	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	57894	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	32268623	usd
	us-gaap	Net Income Loss NetIncomeLoss	51518	usd
	us-gaap	Net Income Loss NetIncomeLoss	-300190	usd
	us-gaap	Depreciation Depreciation	1241455	usd
	us-gaap	Depreciation Depreciation	1232222	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	9552	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	9552	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	3820	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	3920	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	115727	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	57894	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	11000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	10000	usd
	iccc	Non Cash Rent Expense NonCashRentExpense	-4006	usd
	iccc	Non Cash Rent Expense NonCashRentExpense	-5358	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1280525	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	253145	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-495	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1513135	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	328348	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-26847	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39512	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2332	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-782	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-199654	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-271742	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1011993	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	107286	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1750786	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1228655	usd
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-996000	usd
	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	11000	usd
	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	10000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1739786	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-222655	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	4233026	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	425816	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	381008	usd
	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	-19306	usd
	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	2272	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30672	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11693	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1585550	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3865983	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	857757	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3750614	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10185468	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6949937	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11043225	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10700551	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4575	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5125	usd
	us-gaap	Interest Paid Net InterestPaidNet	159396	usd
	us-gaap	Interest Paid Net InterestPaidNet	157418	usd
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	15201	usd
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	74439	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BUSINESS OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ImmuCell Corporation (the “Company”, “we”, “us”, “our”) was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with our initial public offering of common stock. We are an animal health company whose purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. As disclosed in Note 17, “Segment Information”, one of our business segments is dedicated to Scours and the other is focused on Mastitis. We manufacture and market the <b>First Defense<sup>®</sup></b> product line, providing <b>Immediate Immunity™</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>®</sup></b>, a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The global COVID-19 pandemic has created, and continues to create, uncertainty for us. While conditions relating to the pandemic may be improving somewhat, the full impact of this viral outbreak on the global economy, and the duration of such impact, is still uncertain at this time. A combination of the conditions, trends and concerns related to or arising from the pandemic, as well as inflation, rising interest rates and potential recessionary conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations, including the supply of the colostrum we purchase to produce our <b>First Defense<sup>®</sup></b> product line, the demand for our products in the U.S. market and our ability to penetrate or maintain a profitable presence in international markets. We are experiencing price increases and shortages in key components, supportive services, transportation and other supplies that may cause production slowdowns that affect our ability to consistently deliver our products to market on time in accordance with customer demand. Despite some recent favorable trends, we maintain our diligence because this is a risk to our business.</p>
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance for Re-Tain® is being depreciated over 39 years from when a certificate of occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin Drug Substance facility when it was placed in service during the third quarter of 2018. Approximately 87% of these assets are being depreciated over 10 years. We began depreciating the leasehold improvements to our new First Defense® production facility at 175 Industrial Way over the remainder of the 10-year lease term beginning when a certificate of occupancy was issued during the second quarter of 2020.
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	11043225	usd
CY2022Q2	iccc	Inventory Production InventoryProduction	2834000	usd
CY2022Q2	iccc	Bank Debt BankDebt	10698026	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10185468	usd
CY2021Q4	iccc	Bank Debt BankDebt	9139329	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(i) Concentration of Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month Periods<br/> Ended June 30, </b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Six-Month Periods<br/> Ended June 30,</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">24</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"></td><td style="text-align: justify">Amount is less than 10%.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Trade accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,<br/> 2022</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, <br/> 2021</b> </p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Amount is less than 10%.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p>
	iccc	Product Sales To Customers Percentage ProductSalesToCustomersPercentage	0.10	pure
	us-gaap	Depreciation Depreciation	1241455	usd
	us-gaap	Depreciation Depreciation	1232222	usd
	iccc	Total Product Sales Percentage TotalProductSalesPercentage	0.10	pure
	iccc	Trade Accounts Receivable Percentage TradeAccountsReceivablePercentage	0.10	pure
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	4053	usd
CY2021Q2	us-gaap	Advertising Expense AdvertisingExpense	3276	usd
	us-gaap	Advertising Expense AdvertisingExpense	20868	usd
	us-gaap	Advertising Expense AdvertisingExpense	18926	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61635	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23265	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115727	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57894	usd
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	548000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	62000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	78000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	442000	shares
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-684148	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	141113	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	51518	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-300190	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7744567	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7658612	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7743350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7440237	shares
CY2021Q2	iccc	Excess Tax Benefit From Shares Based Compensation Financing Activities ExcessTaxBenefitFromSharesBasedCompensationFinancingActivities	102444	usd
	iccc	Excess Tax Benefit From Shares Based Compensation Financing Activities ExcessTaxBenefitFromSharesBasedCompensationFinancingActivities	38053	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7744567	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7761056	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7781403	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7440237	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	216069	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4603109	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3089974	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our inventory valuation, valuation of goodwill and long-lived assets, valuation of deferred tax assets, accrued expenses, costs of goods sold and useful lives of intangible assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in"> </p>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11043225	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10185468	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1413704	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2694229	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2094848	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	971606	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2049993	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1902299	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	458268	usd
CY2021Q2	us-gaap	Depreciation Depreciation	617527	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	244262	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	268713	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	24088	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	26484	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	268350	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295197	usd
CY2022Q2	iccc	Debt Issuance Costshereafter DebtIssuanceCostshereafter	20280	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42609554	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40886872	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15191424	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13993273	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27418130	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26893599	usd
CY2022Q2	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3894	usd
CY2021Q2	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	2928	usd
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	43305	usd
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	95049	usd
CY2022Q2	us-gaap	Depreciation Depreciation	624609	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	53397	usd
CY2021Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	iccc	Developed Technology Intangible Assets DevelopedTechnologyIntangibleAssets	191040	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1429797	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1614250	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4776	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4776	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9552	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9552	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	66864	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76416	usd
	iccc	Intangible Assets Description IntangibleAssetsDescription	Intangible asset amortization expense is estimated to be $19,104 per year through December 31, 2025.
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	124176	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	66864	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	114624	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76416	usd
CY2022Q2	iccc	Long Term Debt2022 LongTermDebt2022	467508	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	610412	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	726781	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	33463	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	18263	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	441644	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	585939	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	78550	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	82050	usd
CY2022Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	265728	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	199076	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2141	usd
CY2022Q2	iccc	Debt Issuance Costs2026 DebtIssuanceCosts2026	7168	usd
CY2021Q2	us-gaap	Other Income OtherIncome		usd
CY2022Q1	us-gaap	Participating Mortgage Loans Unamortized Debt Discount Amount ParticipatingMortgageLoansUnamortizedDebtDiscountAmount	2000000	usd
CY2022Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.0358	pure
CY2022Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0353	pure
CY2032Q1	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	70170	usd
CY2021Q4	iccc	Minimum Debt Services Coverage Ratio MinimumDebtServicesCoverageRatio	1.35	pure
CY2022Q2	iccc	Debt Principal Repayments DebtPrincipalRepayments	228431	usd
CY2021Q2	iccc	Debt Principal Repayments DebtPrincipalRepayments	190632	usd
	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt	2000000	usd
	iccc	Debt Principal Repayments DebtPrincipalRepayments	425816	usd
	iccc	Debt Principal Repayments DebtPrincipalRepayments	381008	usd
	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2022Q2	iccc	Debt Issuance Costs2022 DebtIssuanceCosts2022	3838	usd
CY2022Q2	iccc	Debt Issuance Costs2023 DebtIssuanceCosts2023	7676	usd
CY2022Q2	iccc	Debt Issuance Costs2024 DebtIssuanceCosts2024	7267	usd
CY2022Q2	iccc	Debt Issuance Costs2025 DebtIssuanceCosts2025	7168	usd
CY2022Q2	iccc	Long Term Debt2023 LongTermDebt2023	1039446	usd
CY2022Q2	iccc	Long Term Debt2024 LongTermDebt2024	1111517	usd
CY2022Q2	iccc	Long Term Debt2025 LongTermDebt2025	1155297	usd
CY2022Q2	iccc	Long Term Debt2026 LongTermDebt2026	1199843	usd
CY2022Q2	iccc	Long Term Debt Thereafter LongTermDebtThereafter	5724415	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	10698026	usd
	iccc	Severance Agreement Description SeveranceAgreementDescription	Effective March 28, 2022, the Company entered into an amended and restated Separation and Deferred Compensation Agreement (the “Deferred Compensation Agreement”) with Mr. Brigham that superseded and replaced in its entirely a March 2020 contract, and the Company entered into an Incentive Compensation Agreement (the “Incentive Agreement”) with Mr. Brigham. Mr. Brigham’s Deferred Compensation Agreement allows Mr. Brigham to be paid all earned and unused paid time off upon separation from the Company for any reason and to receive up to an additional $300,000 in deferred compensation. This deferred compensation payment vests as to $100,000 on January 1, 2023, as to an additional $100,000 on January 1, 2024 and as to the final $100,000 on January 1, 2025, provided that Mr. Brigham is employed by the Company on the applicable vesting dates. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. In addition, upon termination of Mr. Brigham’s employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, the Company agrees to pay Mr. Brigham 100% of his then current base salary.
	iccc	Additional Provides AdditionalProvides	150000	usd
CY2022Q2	iccc	Capital Expenditures Committed CapitalExpendituresCommitted	817000	usd
CY2022Q2	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P7Y7M6D
CY2021Q2	iccc	Operating Lease Weighted Average Remaining Lease Term2 OperatingLeaseWeightedAverageRemainingLeaseTerm2	P8Y7M6D
CY2022Q2	us-gaap	Other Commitment OtherCommitment	138000	usd
CY2022Q2	iccc	Operating Lease Future Minimum Payments Receivable In Three Years OperatingLeaseFutureMinimumPaymentsReceivableInThreeYears	165120	usd
	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	108000	usd
CY2022Q2	iccc	Other Obligations OtherObligations	495000	usd
CY2019Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland, which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our needs in expanding our production capacity for the First Defense® product line. The lease term is 10 years with a right to renew for a second 10-year term and a right of first offer to purchase. At this time, we are not reasonably assured that we would exercise this renewal option in place of other real estate options. A 10-year period is reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. The total lease liability over the initial 10-year term (including inflationary adjustments) aggregates approximately $1,313,698 and includes real estate and personal property taxes, utilities, insurance, maintenance and related building and operating expenses.
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051127	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1081169	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	30237	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	29499	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	60228	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	58998	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	10350	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	10350	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	20700	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	20700	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	40587	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	39849	usd
	us-gaap	Lease Cost LeaseCost	80928	usd
	us-gaap	Lease Cost LeaseCost	79698	usd
CY2022Q2	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0477	pure
CY2021Q2	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0477	pure
	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0477	pure
	iccc	Operating Lease Weighted Average Discount Rate Percent1 OperatingLeaseWeightedAverageDiscountRatePercent1	0.0477	pure
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable In Two Years OperatingLeasesFutureMinimumPaymentReceivableInTwoYears	81051	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2154044	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1707328	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable In Four Years OperatingLeasesFutureMinimumPaymentReceivableInFourYears	168210	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable In Five Years OperatingLeasesFutureMinimumPaymentReceivableInFiveYears	171383	usd
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.08
CY2022Q2	iccc	Operating Leases Future Minimum Payments Receivable In Six Years OperatingLeasesFutureMinimumPaymentsReceivableInSixYears	174640	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payments Receivable In Seven Years OperatingLeasesFutureMinimumPaymentsReceivableInSevenYears	177970	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable Thereafter OperatingLeasesFutureMinimumPaymentReceivableThereafter	381694	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable OperatingLeasesFutureMinimumPaymentReceivable	1320068	usd
CY2022Q2	iccc	Less Imputed Interest Discount Effect Of Cash Flows LessImputedInterestDiscountEffectOfCashFlows	238899	usd
CY2022Q2	iccc	Operating Leases Future Minimum Payment Receivable Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentReceivableRemainderOfFiscalYear	1081169	usd
CY2016Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1123810	shares
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5900000	usd
CY2016Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5313000	usd
CY2017Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	417807	shares
CY2017Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.3
CY2017Q4	iccc	Registration Statement Description RegistrationStatementDescription	in an underwritten public offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of approximately $3,050,000 and resulting in net proceeds to the Company of approximately $2,734,000 (after deducting underwriting discounts and offering expenses incurred in connection with the equity financing).
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3050000	usd
CY2017Q4	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	2734000	usd
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1636364	shares
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000000	usd
CY2019Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	8303000	usd
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	515156	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.25
CY2021Q2	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4250000	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4233000	usd
CY2017Q2	iccc	Stock Option And Incentive Plan Description StockOptionAndIncentivePlanDescription	In June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the “2017 Plan”) pursuant to the provisions of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of the Company’s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan by 350,000 shares from 300,000 shares to 650,000 shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June 2022.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.38
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.78
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.26
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1138767	usd
	iccc	Total Product Sales TotalProductSales	9861056	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.97
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.13
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.26
CY2022Q2	iccc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested	6.79
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.26
	iccc	Stock Options Covering Shares StockOptionsCoveringShares	5000	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30672	usd
CY2022Q2	iccc	Fair Value Assumptions Risk Free Interests Rate FairValueAssumptionsRiskFreeInterestsRate	0.0338	pure
CY2021Q2	iccc	Fair Value Assumptions Risk Free Interests Rate FairValueAssumptionsRiskFreeInterestsRate	0.009	pure
	iccc	Fair Value Assumptions Risk Free Interests Rate FairValueAssumptionsRiskFreeInterestsRate	0.0262	pure
	iccc	Fair Value Assumptions Risk Free Interests Rate FairValueAssumptionsRiskFreeInterestsRate	0.0086	pure
CY2022Q2	iccc	Fair Value Assumptions Expected Dividend Rates FairValueAssumptionsExpectedDividendRates	0	pure
CY2021Q2	iccc	Fair Value Assumptions Expected Dividend Rates FairValueAssumptionsExpectedDividendRates	0	pure
	iccc	Fair Value Assumptions Expected Dividend Rates FairValueAssumptionsExpectedDividendRates	0	pure
	iccc	Fair Value Assumptions Expected Dividend Rates FairValueAssumptionsExpectedDividendRates	0	pure
CY2022Q2	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.53	pure
CY2021Q2	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.54	pure
	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.53	pure
	iccc	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	0.54	pure
CY2022Q2	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P6Y6M
CY2021Q2	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P4Y7M6D
	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P6Y6M
	iccc	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P4Y9M18D
	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).
CY2022Q2	iccc	Total Product Sales TotalProductSales	3861372	usd
CY2022Q2	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021Q2	iccc	Total Product Sales TotalProductSales	4541810	usd
CY2021Q2	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	659239	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	528329	usd
CY2022Q2	iccc	Operating Activities OperatingActivities	2326335	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-619007	usd
	iccc	Total Product Sales TotalProductSales	8648956	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3861372	usd
CY2022Q2	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4541810	usd
CY2021Q2	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9861056	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8648956	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021	iccc	Total Product Sales TotalProductSales	19242969	usd
CY2021	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2020	iccc	Total Product Sales TotalProductSales	15342204	usd
CY2020	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19242969	usd
CY2021	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15342204	usd
CY2020	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2021Q2	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	4541810	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2467489	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	11000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	10000	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	26187	usd
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	5022	usd
	us-gaap	Interest Income Other InterestIncomeOther	33375	usd
	us-gaap	Interest Income Other InterestIncomeOther	7979	usd
CY2022Q2	us-gaap	Other Income OtherIncome	60	usd
	us-gaap	Other Income OtherIncome	912	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	2074321	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000107	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	436982	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	63993	usd
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	74395	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	120167	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	141073	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1915	usd
CY2021Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1960	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3820	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3920	usd
CY2022Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1148	usd
CY2021Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002	pure
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2295	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.04	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Tax Credit Carryforward Description TaxCreditCarryforwardDescription	federal net operating loss carryforwards of $14,734,684 of which $13,022,777 do not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of $1,440,707 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $557,795 that expire in 2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $775,473 that expire in 2022 through 2042 (if not utilized before then).
	iccc	Noncash Income Tax Expense NoncashIncomeTaxExpense	563252	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3861372	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	421724	usd
CY2021Q2	iccc	Operating Activities OperatingActivities	1858813	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	215508	usd
CY2022Q2	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	45983849	usd
CY2021Q2	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	43729643	usd
CY2022Q2	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	631299	usd
CY2021Q2	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	624263	usd
CY2022Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	943290	usd
CY2021Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	879339	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	9861056	usd
CY2020	iccc	Operating Activities OperatingActivities	8243179	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1380353	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5050505	usd
	us-gaap	Gross Profit GrossProfit	4810551	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2174702	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1470740	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	991129	usd
	iccc	Operating Activities OperatingActivities	4636571	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	173980	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	8648956	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4972446	usd
	us-gaap	Gross Profit GrossProfit	3676510	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2031171	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	957580	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	846876	usd
	iccc	Operating Activities OperatingActivities	3835627	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-159117	usd
CY2022Q2	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	45983849	usd
CY2021Q2	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	43729643	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1254827	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1245694	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1750786	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1228655	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	19242969	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10587040	usd
CY2021	us-gaap	Gross Profit GrossProfit	8655929	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4168518	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2503926	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1726100	usd
CY2021	iccc	Operating Activities OperatingActivities	8398544	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	257385	usd
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	15342204	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8479378	usd
CY2020	us-gaap	Gross Profit GrossProfit	6862826	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4354627	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2167899	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1720653	usd
CY2021Q4	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	44465688	usd
CY2020Q4	iccc	Total Assets Three Month Of June Thirty Two Thousand Twenty Two TotalAssetsThreeMonthOfJuneThirtyTwoThousandTwentyTwo	40349594	usd
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2468981	usd
CY2020	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2450007	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2608649	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4072539	usd
	dei	Amendment Flag AmendmentFlag	false
	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt		usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	357725	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	319133	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	15020	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	55490	usd
	iccc	Employee Benefits Description EmployeeBenefitsDescription	We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate.
	us-gaap	Defined Benefit Plans General Information DefinedBenefitPlansGeneralInformation	We currently match 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan.
CY2022Q2	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	37979	usd
CY2021Q2	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	38447	usd
	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	79843	usd
	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	71119	usd
	iccc	Excess Tax Benefit From Shares Based Compensation Financing Activities ExcessTaxBenefitFromSharesBasedCompensationFinancingActivities		usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2022Q2	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt		usd
CY2021Q2	iccc	Proceeds From Issuances Of Debt ProceedsFromIssuancesOfDebt		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Central Index Key EntityCentralIndexKey	0000811641

Files In Submission

Name	View Source	Status
0001213900-22-046861-index-headers.html	Edgar Link	pending
0001213900-22-046861-index.html	Edgar Link	pending
0001213900-22-046861.txt	Edgar Link	pending
0001213900-22-046861-xbrl.zip	Edgar Link	pending
f10q0622ex31_immucell.htm	Edgar Link	pending
f10q0622ex32_immucell.htm	Edgar Link	pending
f10q0622ex4-1_immucell.htm	Edgar Link	pending
f10q0622_immucellcorp.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iccc-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
iccc-20220630_cal.xml	Edgar Link	unprocessable
iccc-20220630_lab.xml	Edgar Link	unprocessable
iccc-20220630_pre.xml	Edgar Link	unprocessable
iccc-20220630_def.xml	Edgar Link	unprocessable
f10q0622_immucellcorp_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCC
IMMUCELL CORP /DE/ Stock $iccc

2022 Q3 Form 10-Q Financial Statement

#000121390022046861 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC IMMUCELL CORP /DE/ Stock $iccc

2022 Q3 Form 10-Q Financial Statement

#000121390022046861 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC
IMMUCELL CORP /DE/ Stock $iccc